Apomorphine: A Different Side to ED Treatment

The name is misleading. Apomorphine is not an opioid and has nothing to do with morphine. It's a dopamine agonist: it activates dopamine receptors in the part of the brain that drives arousal. That's the paraventricular nucleus of the hypothalamus, where the brain initiates an erection.¹ A PDE5 inhibitor waits at the end of the chain to strengthen a signal that has already arrived. Apomorphine works at the beginning, boosting the signal itself.

Apomorphine has been used safely in medicine for decades, mainly in Parkinson's disease, where its dopamine activity helps with movement. Its effect on erections was documented along the way: men given apomorphine for other reasons developed firmer and more reliable erections, and the mechanism made sense. Stimulate the brain's dopamine arousal circuitry, and the rest of the erectile process follows.

Apomorphine has been tested in large, placebo-controlled trials in thousands of men, against the most demanding measure in the field: the share of attempts that produced an erection firm enough for intercourse.

The results held up. In pooled placebo-controlled trials, sublingual apomorphine produced erections firm enough for intercourse in about half of attempts, compared with a third on placebo.² ³ Onset was fast, with a median time to erection of about 18 minutes and most erections within half an hour.³ The benefit was strongest in men with mild to moderate ED, including men with common conditions like hypertension, diabetes, and heart disease.

Apomorphine only works if it's delivered correctly. Swallowed as an ordinary pill, the liver breaks it down before it reaches the brain. That means you would need a large dose to get any effect, with higher risks of side effects.

Dissolved sublingually, under the tongue, it absorbs straight into the bloodstream and bypasses the liver. A small 2 mg dose reaches the brain quickly, helps produce the erection, and typically causes minimal side effects.³ It also isn't affected by food. (More on the science of the route in Why Sublingual Delivery Matters for ED.)

Apomorphine is not the only compound that can theoretically act on the brain to treat ED. But it is the one with the best combination of evidence, mechanism, and drug delivery. The alternatives show why.

Bremelanotide acts on a different brain pathway, the melanocortin system, and has real Phase II data in men with ED.⁴ But it isn't a pill. It's given by injection, with narrow timing, and in the U.S. it's only approved for libido in women, not ED in men. Be skeptical of any version sold as a tablet or troche: bremelanotide is a large peptide with extremely low absorption by mouth, even sublingually.

Oxytocin is a hormone the brain releases during arousal and bonding, which is why it comes up often as an ED candidate. The biology is plausible, but the human evidence for treating ED is close to zero. Again, be skeptical of any treatment touting its benefits.

Vitamin B12 and similar "stack" ingredients contain no arousal mechanism at all. Unless you're actually deficient, it likely won't help with erections. When you see them on an ED label, be skeptical yet again. That's marketing, not treatment.

Of every compound that acts on the brain's role in arousal, apomorphine is the only one with both a strong evidence base and a delivery method that works in the real world.

I prescribe apomorphine for men who haven't responded well to PDE5 inhibitors. Its real strength shows when both halves of the process are treated together. Paired with a PDE5 inhibitor, it can help produce firmer and longer-lasting erections. (See The Case for Combination ED Treatment.)

Apomorphine works, it's safe, and it's backed by decades of clinical use and placebo-controlled trials. It treats the half of the problem that PDE5 inhibitors leave untouched.

If you've tried PDE5 inhibitors and been disappointed, the question worth asking a provider may not be to take a stronger version of the same pill. Perhaps it's time to treat the part of the process that hasn't yet been addressed.